<SEC-DOCUMENT>0001193125-23-188839.txt : 20230718
<SEC-HEADER>0001193125-23-188839.hdr.sgml : 20230718
<ACCEPTANCE-DATETIME>20230718160132
ACCESSION NUMBER:		0001193125-23-188839
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20230713
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230718
DATE AS OF CHANGE:		20230718

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ACADIA PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001070494
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				061376651
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50768
		FILM NUMBER:		231094257

	BUSINESS ADDRESS:	
		STREET 1:		3611 VALLEY CENTRE DRIVE
		STREET 2:		SUITE 300
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		858-558-2871

	MAIL ADDRESS:	
		STREET 1:		3611 VALLEY CENTRE DRIVE
		STREET 2:		SUITE 300
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d533087d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:acad="http://www.acadia-pharm.com/20230713" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityRegistrantName" name="dei:EntityRegistrantName" contextRef="duration_2023-07-13_to_2023-07-13">ACADIA PHARMACEUTICALS INC</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2023-07-13_to_2023-07-13">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2023-07-13_to_2023-07-13">0001070494</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="acad-20230713.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2023-07-13_to_2023-07-13"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001070494</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-13</xbrli:startDate> <xbrli:endDate>2023-07-13</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2023-07-13_to_2023-07-13">8-K</ix:nonNumeric></span></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2023-07-13_to_2023-07-13" format="ixt:datemonthdayyearen">July&#160;13, 2023</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <span style=" -sec-ix-hidden:Hidden_dei_EntityRegistrantName">Acadia Pharmaceuticals Inc.</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of Registrant as Specified in Its Charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2023-07-13_to_2023-07-13" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2023-07-13_to_2023-07-13">000-50768</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2023-07-13_to_2023-07-13">06-1376651</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or Other Jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of Incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2023-07-13_to_2023-07-13">12830 El Camino Real</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2023-07-13_to_2023-07-13">Suite 400</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2023-07-13_to_2023-07-13">San Diego</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2023-07-13_to_2023-07-13" format="ixt-sec:stateprovnameen">California</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2023-07-13_to_2023-07-13">92130</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of Principal Executive Offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s Telephone Number, Including Area Code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2023-07-13_to_2023-07-13">(858)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2023-07-13_to_2023-07-13">558-2871</ix:nonNumeric></span></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">N/A</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2023-07-13_to_2023-07-13" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2023-07-13_to_2023-07-13" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2023-07-13_to_2023-07-13" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2023-07-13_to_2023-07-13" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br />Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2023-07-13_to_2023-07-13">Common Stock, par value $0.0001 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2023-07-13_to_2023-07-13">ACAD</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2023-07-13_to_2023-07-13" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 (&#167; <span style="white-space:nowrap">240.12b-2</span> of this chapter).</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#160;&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2023-07-13_to_2023-07-13" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;1.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&#160;13, 2023, Acadia Pharmaceuticals Inc. (the &#8220;Company&#8221;) and Neuren Pharmaceuticals Limited (&#8220;Neuren&#8221;) entered into a joint venture and license agreement (the &#8220;License Agreement&#8221;) for the global commercialization and development of trofinetide and of Neuren&#8217;s development candidate <span style="white-space:nowrap">NNZ-2591.</span> The License Agreement amended and restated the <span style="white-space:nowrap">pre-existing</span> license agreement between the Company and Neuren, dated August&#160;6, 2018 (the &#8220;Initial License&#8221;), pursuant to which Neuren granted to the Company exclusive North American rights to develop and commercialize trofinetide for Rett syndrome and other indications. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the License Agreement, Neuren granted to the Company a worldwide, exclusive license to develop and commercialize any product developed by or on behalf of Neuren or the Company containing a trofinetide compound as an active ingredient (a &#8220;Trofinetide Product&#8221;) for all indications. In addition, pursuant to the License Agreement, Neuren granted to the Company a worldwide, exclusive license to develop and commercialize any product developed by or on behalf of Neuren or the Company containing a <span style="white-space:nowrap">NNZ-2591</span> compound as an active ingredient (a <span style="white-space:nowrap">&#8220;NNZ-2591</span> Product&#8221;) for the treatment of Rett syndrome and Fragile X syndrome (the &#8220;Acadia <span style="white-space:nowrap">NNZ-2591</span> Field&#8221;). Neuren may conduct development and commercialization of <span style="white-space:nowrap">NNZ-2591</span> outside of the Acadia <span style="white-space:nowrap">NNZ-2591</span> Field. The joint steering committee established under the Initial License will be and become the joint steering committee under the License Agreement, and will oversee efforts by the parties. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the License Agreement, the Company will make an upfront payment to Neuren of $100.0&#160;million. This payment is in addition to the upfront payment of $10.0&#160;million previously paid by the Company under the Initial License and the milestone payments in the aggregate of $50.0&#160;million previously paid by the Company upon achieving certain development milestones for trofinetide. Neuren is also eligible to receive future milestone payments of up to $405.0&#160;million for each of trofinetide and <span style="white-space:nowrap">NNZ-2591,</span> based on the achievement of certain development and annual net sales milestones in North America. Outside of North America, Neuren is eligible to receive milestone payments based the achievement of certain development and annual net sales milestones for each of trofinetide and <span style="white-space:nowrap">NNZ-2591</span> in certain regions, including payments upon the Company&#8217;s first commercial sale of each of trofinetide and <span style="white-space:nowrap">NNZ-2591</span> in each region, as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:26%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:24%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:24%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:23%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">First&#160;Commercial&#160;Sale</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Total Sales Milestones</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:middle" rowspan="2" align="center"><span style="font-weight:bold">Europe</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Rett Syndrome</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">$35.0&#160;million</td>
<td style="vertical-align:bottom" rowspan="2">&#160;&#160;</td>
<td rowspan="2" style="vertical-align:middle;white-space:nowrap" align="center">Up&#160;to&#160;$170.0&#160;million</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Second Indication</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">$10.0&#160;million</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:middle" rowspan="2" align="center"><span style="font-weight:bold">Japan</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Rett Syndrome</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">$15.0&#160;million</td>
<td style="vertical-align:bottom" rowspan="2">&#160;&#160;</td>
<td rowspan="2" style="vertical-align:middle;white-space:nowrap" align="center">Up&#160;to&#160;$110.0&#160;million</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Second Indication</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">$3.75&#160;million</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:middle" align="center"><span style="font-weight:bold">Rest of World</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">&#8212;&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:middle;white-space:nowrap" align="center">Up&#160;to&#160;$83.0&#160;million</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neuren will also be eligible to receive tiered, escalating, double-digit percentage royalties based on net sales of Trofinetide Products and/or <span style="white-space:nowrap">NNZ-2591</span> Products by the Company, its affiliates or sublicensees, subject to reductions in certain circumstances. Royalties will be payable under the License Agreement on a <span style="white-space:nowrap"><span style="white-space:nowrap">product-by-product</span></span> and <span style="white-space:nowrap"><span style="white-space:nowrap">country-by-country</span></span> basis, commencing on the date of execution of the License Agreement and ending on the last to occur of (a)&#160;the expiration date of the last valid claim that would be infringed by an authorized sale of the relevant product in the relevant country, (b)&#160;the expiration date of the term of any data exclusivity right in such country, and (c) 10 years after the date of the first commercial sale of the relevant product in such country. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The License Agreement may be terminated by Neuren with respect to a given product by providing 10 business days&#8217; prior written notice to the Company if, with respect to such product, (a)&#160;the Company challenges the validity of certain Neuren intellectual property or (b)&#160;the Company ceases certain commercialization activities with respect to trofinetide in Rett syndrome. The License Agreement may be terminated by the Company at any time in its entirety or on a <span style="white-space:nowrap"><span style="white-space:nowrap">product-by-product</span></span> basis by providing 90 business days&#8217; prior written notice to Neuren. In addition, either party may terminate the License Agreement upon written notice for the other party&#8217;s uncured material breach, subject to an extension of the cure period under certain circumstances. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the terms of the License Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the License Agreement, a copy of which will be filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) as an exhibit to a subsequent filing with the SEC. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;2.02</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Results of Operations and Financial Condition. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&#160;13, 2023, the Company issued a press release announcing the entry into the License Agreement and announcing preliminary net sales for Q2 2023 and updated net sales guidance for Q3 2023 and full year 2023. A copy of the press release is furnished herewith as Exhibit 99.1. Pursuant to the rules and regulations of the SEC, such exhibit and the information set forth therein and in this Item 2.02 have been furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to liability under that section nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing regardless of any general incorporation language. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Forward-Looking Statements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Current Report on Form <span style="white-space:nowrap">8-K</span> contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;potential&#8221; and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on the Company&#8217;s expectations and assumptions as of the date of this Current Report. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this Current Report include, but are not limited to, statements regarding future activities under the License Agreement; approvals of product candidates developed pursuant to the License Agreement; potential future payments that may be become payable by the Company pursuant to the License Agreement; the benefits to be derived from the Company&#8217;s products and product candidates; the Company&#8217;s financial and operating performance; expected future clinical and regulatory milestones; and the timing of the initiation and/or completion of the Company&#8217;s clinical, regulatory, and other development activities. Many factors may cause differences between current expectations and actual results, including the risks and uncertainties inherent in drug development, approval and commercialization. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this Current Report are discussed in the Company&#8217;s filings with the SEC, including the sections titled &#8220;Risk Factors&#8221; contained therein. Except as required by law, the Company assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td style="width:92%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit<br />&#160;&#160;&#160;&#160;No.&#160;&#160;&#160;&#160;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d533087dex991.htm">Press Release dated July&#160;13, 2023 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:3%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">Acadia Pharmaceuticals Inc.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Dated: July&#160;18, 2023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Austin D. Kim</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Austin D. Kim</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Executive Vice President, General Counsel&#160;&amp; Secretary</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d533087dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Acadia Pharmaceuticals Acquires <FONT STYLE="white-space:nowrap">Ex-North</FONT> American Rights to Trofinetide and Global Rights to
Neuren&#146;s <FONT STYLE="white-space:nowrap">NNZ-2591</FONT> in Rett Syndrome and Fragile X Syndrome </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&#151; Expanded agreement
follows Acadia&#146;s April 2023 U.S. launch of DAYBUE<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> (trofinetide) as the first and only drug approved for the treatment of Rett syndrome </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&#151; Acadia provides DAYBUE launch update and announces second quarter preliminary net sales and guidance for third quarter </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&#151; Company to host conference call and webcast today at 4:30 p.m. Eastern Time </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>San Diego, Calif. </B>&#150; July&nbsp;13, 2023 &#150; Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that it has expanded its current
licensing agreement for trofinetide with Neuren Pharmaceuticals to acquire <FONT STYLE="white-space:nowrap">ex-North</FONT> American rights to the drug as well as global rights in Rett syndrome and Fragile X syndrome to Neuren&#146;s development
candidate <FONT STYLE="white-space:nowrap">NNZ-2591.</FONT> In April of this year, Acadia launched trofinetide in the United States under the brand name DAYBUE as the first and only drug approved for the treatment of Rett syndrome. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;This expanded worldwide agreement solidifies Acadia&#146;s position as the global leader in addressing the unmet needs of people with Rett
syndrome,&#148; said Steve Davis, Acadia&#146;s President and Chief Executive Officer. &#147;We have successfully delivered DAYBUE, the first <FONT STYLE="white-space:nowrap">FDA-approved</FONT> therapy that treats the core symptoms of Rett
syndrome, and are deeply committed to broadening access to this important therapy for patients worldwide.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to expanding access to
trofinetide outside of North America, this agreement gives Acadia exclusive worldwide rights to <FONT STYLE="white-space:nowrap">NNZ-2591</FONT> in both Rett syndrome and Fragile X syndrome. <FONT STYLE="white-space:nowrap">NNZ-2591</FONT> is an
investigational synthetic analogue of cyclo-glycyl-proline (cGP) which results from the breakdown of human insulin-like growth factor 1 <FONT STYLE="white-space:nowrap">(IGF-1).</FONT> <FONT STYLE="white-space:nowrap">NNZ-2591</FONT> is currently
under development by Neuren in four other rare neurodevelopmental syndromes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Execution of this agreement advances Acadia&#146;s corporate strategy to
expand our rare disease business. This deal also enables Acadia to leverage insights from our successful U.S. launch of DAYBUE in other global territories. In addition, this expansion will further advance the global potential of Acadia&#146;s
current development portfolio. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acadia intends to submit a New Drug Submission (NDS) for trofinetide in Canada in the next 18 months with plans for
Europe, Asia and other regions to be announced at a later date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Financial Terms </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the expanded agreement, Neuren will receive an upfront payment of US $100&nbsp;million and is eligible to receive additional potential
downstream milestone and royalty payments earned separately for trofinetide and <FONT STYLE="white-space:nowrap">NNZ-2591.</FONT> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Outside of North America, Neuren is eligible to receive additional payments for trofinetide upon the
achievement of specified revenue milestones as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="78%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">First Commercial Sales Milestones</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Total Sales Milestones<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Europe</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$35M (Rett); $10M (2<SUP STYLE="font-size:75%; vertical-align:top">nd</SUP> indication)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Up to $170M</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Japan</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$15M (Rett); $4M (2<SUP STYLE="font-size:75%; vertical-align:top">nd</SUP> indication)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Up to $110M</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Rest of World</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">-0-</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Up to $83M</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each region&#146;s sales milestones are divided into four distinct milestones based upon escalating annual net
sales thresholds as defined in the agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neuren will also receive tiered royalties from the
<FONT STYLE="white-space:nowrap">mid-teens</FONT> to <FONT STYLE="white-space:nowrap">low-twenties</FONT> percent of trofinetide net sales outside of North America. In North America, all milestones and royalties for trofinetide remain unchanged from
Acadia&#146;s previously existing North American license agreement with Neuren. Potential future payments to Neuren related to <FONT STYLE="white-space:nowrap">NNZ-2591</FONT> in Rett syndrome and Fragile X syndrome are identical to the payments for
trofinetide in each of North America and outside North America. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preliminary Second Quarter Revenues and Updated Guidance </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DAYBUE </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">DAYBUE 2Q 2023 preliminary net sales: $21 to $23&nbsp;million. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">DAYBUE <U>3Q</U> 2023 net sales guidance: $45 to $55&nbsp;million. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NUPLAZID </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">NUPLAZID 2Q 2023 preliminary net sales: $140 to $144&nbsp;million. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">NUPLAZID <U>Full Year</U> 2023 net sales guidance: $530 to $545&nbsp;million. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Conference Call and Webcast Information </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acadia will
discuss the exclusive worldwide licensing of trofinetide and <FONT STYLE="white-space:nowrap">NNZ-2591</FONT> via conference call and webcast today at 4:30 p.m. Eastern Time. The conference call will be available on Acadia&#146;s website,
<U>www.acadia.com</U> under the investors section and will be archived there until August&nbsp;12, 2023. The conference call may also be accessed by registering for the call <U>here</U>. Once registered, participants will receive an email with the <FONT
STYLE="white-space:nowrap">dial-in</FONT> number and unique PIN number to use for accessing the call. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>About Rett Syndrome </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rett syndrome is a rare, complex, neurodevelopmental disorder that may occur over four stages and affects approximately 6,000 to 9,000 patients in the U.S.,
with approximately 4,500 patients currently diagnosed according to an analysis of healthcare claims data.<SUP STYLE="font-size:75%; vertical-align:top"><FONT STYLE="white-space:nowrap">1-4</FONT></SUP> Worldwide, incidence rates for Rett syndrome
are similar in countries across the globe, with prevalence varying according to population size, with the number of patients in Europe estimated to be larger and that of Japan&#146;s smaller. A child with Rett syndrome exhibits an early period of
apparently normal development until six to 18 months, when their skills seem to slow down or stagnate. This is typically followed by a duration of regression when the child loses acquired communication skills and purposeful hand use. The child may
then experience a plateau period in which they show mild recovery in cognitive interests, but body movements remain severely diminished. As they age, those living with Rett may continue to experience a stage of motor deterioration which can last the
rest of the patient&#146;s life.<SUP STYLE="font-size:75%; vertical-align:top">3</SUP> Rett syndrome is typically caused by a genetic mutation on the MECP2 gene.<SUP STYLE="font-size:75%; vertical-align:top">5</SUP> In preclinical studies,
deficiency in MeCP2 function has been shown to lead to impairment in synaptic communication, and the deficits in synaptic function may be associated with Rett manifestations.<SUP STYLE="font-size:75%; vertical-align:top"><FONT
STYLE="white-space:nowrap">5-7</FONT></SUP> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Symptoms of Rett syndrome may also include development of hand stereotypies, such as hand wringing and
clapping, and gait abnormalities.<SUP STYLE="font-size:75%; vertical-align:top">8</SUP> Most Rett patients typically live into adulthood and require <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">round-the-clock</FONT></FONT>
care.<SUP STYLE="font-size:75%; vertical-align:top">2,9</SUP> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>About DAYBUE<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> (trofinetide)
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Trofinetide is a synthetic version of a naturally occurring molecule known as the tripeptide glycine-proline-glutamate (GPE). The mechanism by which
trofinetide exerts therapeutic effects in patients with Rett syndrome is unknown. In animal studies, trofinetide has been shown to increase branching of dendrites and synaptic plasticity
signals.<SUP STYLE="font-size:75%; vertical-align:top">10,11</SUP> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Important Safety Information for DAYBUE<SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP> (trofinetide) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Warnings and Precautions </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Diarrhea</B>: In a <FONT STYLE="white-space:nowrap">12-week</FONT> study and in long-term studies, an
aggregate of 85% of patients treated with DAYBUE experienced diarrhea. In those treated with DAYBUE, 49% either had persistent diarrhea or recurrence after resolution despite dose interruptions, reductions, or concomitant antidiarrheal therapy.
Diarrhea severity was of mild or moderate severity in 96% of cases. In the <FONT STYLE="white-space:nowrap">12-week</FONT> study, antidiarrheal medication was used in 51% of patients treated with DAYBUE. Patients should stop taking laxatives before
starting DAYBUE. If diarrhea occurs, patients should notify their healthcare provider, consider starting antidiarrheal treatment, and monitor hydration status and increase oral fluids, if needed. Interrupt, reduce dose, or discontinue DAYBUE if
severe diarrhea occurs or if dehydration is suspected. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Weight Loss</B>: In the <FONT STYLE="white-space:nowrap">12-week</FONT> study, 12% of patients treated with
DAYBUE experienced weight loss of greater than 7% from baseline, compared to 4% of patients who received placebo. In long-term studies, 2.2% of patients discontinued treatment with DAYBUE due to weight loss. Monitor weight and interrupt, reduce
dose, or discontinue DAYBUE if significant weight loss occurs. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Adverse Reactions: </B>The common adverse reactions (&#8805;5% for DAYBUE-treated patients and at least 2%
greater than in placebo) reported in the <FONT STYLE="white-space:nowrap">12-week</FONT> study were diarrhea (82% vs 20%), vomiting (29% vs 12%), fever (9% vs 4%), seizure (9% vs 6%), anxiety (8% vs 1%), decreased appetite (8% vs 2%), fatigue (8% vs
2%), and nasopharyngitis (5% vs 1%). </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Drug Interactions: Effect of DAYBUE on other Drugs </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">DAYBUE is a weak CYP3A4 inhibitor; therefore, plasma concentrations of CYP3A4 substrates may be increased if
given concomitantly with DAYBUE. Closely monitor when DAYBUE is used in combination with orally administered CYP3A4 sensitive substrates for which a small change in substrate plasma concentration may lead to serious toxicities.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Plasma concentrations of OATP1B1 and OATP1B3 substrates may be increased if given concomitantly with DAYBUE.
Avoid the concomitant use of DAYBUE with OATP1B1 and OATP1B3 substrates for which a small change in substrate plasma concentration may lead to serious toxicities. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Use in Specific Population: Renal Impairment </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">DAYBUE is not recommended for patients with moderate or severe renal impairment. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DAYBUE is available as an oral solution (200 mg/mL). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please read the accompanying full <U>Prescribing Information</U>, also available at <U>DAYBUE.com</U> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>About Fragile X Syndrome </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fragile X syndrome is the most
common inherited cause of intellectual disability and the most common known cause of autism. Fragile X syndrome is due to a gene mutation on the X chromosome that impacts the FMRP protein, which is responsible for regulating the synapses of nerve
cells. The full mutation causes Fragile X syndrome. It is estimated that between one in 4,000 and one in 7,000 males and between one in 6,000 and one in 11,000 females have the full mutation. Generally, males are more severely affected, with
approximately 50% of the females having some features of the syndrome. Clinically, Fragile X syndrome is characterized by intellectual handicap, hyperactivity and attentional problems, autistic symptoms, anxiety, emotional lability and epilepsy.<SUP
STYLE="font-size:75%; vertical-align:top">12,13</SUP> Currently, there are no medicines approved for the treatment of Fragile X syndrome. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>About Acadia
Pharmaceuticals </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acadia is advancing breakthroughs in neuroscience to elevate life. For 30 years we have been working at the forefront of healthcare to
bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapies for hallucinations and delusions associated with Parkinson&#146;s disease psychosis and for the treatment of Rett syndrome. Our
clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Prader-Willi syndrome, Alzheimer&#146;s disease psychosis and neuropsychiatric symptoms in central nervous system disorders. For more information,
visit us at <U>www.acadia.com</U> and follow us on <U>LinkedIn</U> and <U>Twitter</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Forward-Looking Statements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include but are not limited to
statements regarding the timing of future events. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those
projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug development, approval and commercialization. For a discussion of these and other factors, please refer to Acadia&#146;s annual report
on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2022, as well as Acadia&#146;s subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this
cautionary statement and Acadia undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>References </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Acadia Pharmaceuticals Inc, Data on file. RTT US Prevalence. March 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fu C, Armstrong D, Marsh E, et al. Consensus guidelines on managing Rett syndrome across the lifespan. <I>BMJ
Paediatrics Open</I>. 2020; 4: <FONT STYLE="white-space:nowrap">1-14.</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Kyle SM, Vashi N, Justice MJ. Rett syndrome: a neurological disorder with metabolic components. <I>Open
Biol</I>. 2018; 8: 170216. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">4</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Acadia Pharmaceuticals Inc, Data on file. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">5</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amir RE, Van den Veyver IB, Wan M, et al. Rett syndrome is caused by mutations in <FONT
STYLE="white-space:nowrap">X-linked</FONT> MECP2, encoding methyl-CpG-binding protein 2. Nat Genet. 1999; 23(2): <FONT STYLE="white-space:nowrap">185-188.</FONT> </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">6</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fukuda T, Itoh M, Ichikawa T, et al. Delayed maturation of neuronal architecture and synaptogenesis in cerebral
cortex of Mecp2-deficient mice. <I>J&nbsp;Neuropathol Exp Neurol</I>. 2005; 64(6): <FONT STYLE="white-space:nowrap">537-544.</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">7</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Asaka Y, Jugloff DG, Zhang L, et al. Hippocampal synaptic plasticity is impaired in the Mecp2-null mouse model
of Rett syndrome. <I>Neurobiol Dis</I>. 2006; 21(1): <FONT STYLE="white-space:nowrap">217-227.</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">8</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Neul JL, Kaufmann WE, Glaze DG, et al. Rett syndrome: revised diagnostic criteria and nomenclature. <I>Ann
Neurol</I>. 2010; 68(6): <FONT STYLE="white-space:nowrap">944-950.</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">9</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Daniel C, Tarquinio DO, Hou W, et al. The changing face of survival in Rett syndrome and MECP2-related
disorders. <I>Pediatr Neurol</I>. 2015; 53(5): <FONT STYLE="white-space:nowrap">402-411.</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">10</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Tropea D, Giacometti E, Wilson NR, et al. Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice.
<I>Proc Natl Acad Sci USA</I>. 2009; 106(6): 2029-2034. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">11</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Acadia Pharmaceuticals Inc, Data on file. Study Report <FONT STYLE="white-space:nowrap">2566-026.</FONT> 2010.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">12</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Neuren Pharmaceuticals. Fragile X Syndrome. Retrieved from <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">https://www.neurenpharma.com/products/trofinetide/fragile-x-syndrome.</FONT></FONT> Accessed July&nbsp;13, 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">13</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">UpToDate. Fragile X syndrome: Clinical features and diagnosis in children and adolescents. Retrieved from <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">https://www.uptodate.com/contents/fragile-x-syndrome-clinical-features-and-diagnosis-in-children-and-adolescents#H3365848815.</FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT> Accessed July&nbsp;13, 2023.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Media Contact: </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acadia
Pharmaceuticals Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deb Kazenelson </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(818) <FONT
STYLE="white-space:nowrap">395-3043</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">media@acadia-pharm.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investor Contact: </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acadia Pharmaceuticals Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jessica Tieszen </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(858)
<FONT STYLE="white-space:nowrap">261-2950</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ir@acadia-pharm.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>acad-20230713.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 7/18/2023 11:37:26 PM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2022"
  xmlns:acad="http://www.acadia-pharm.com/20230713"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.acadia-pharm.com/20230713"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" namespace="http://xbrl.sec.gov/naics/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="acad-20230713_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="acad-20230713_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.acadia-pharm.com//20230713/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>acad-20230713_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 7/18/2023 11:37:26 PM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>acad-20230713_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 7/18/2023 11:37:26 PM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.acadia-pharm.com//20230713/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="acad-20230713.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.acadia-pharm.com//20230713/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140268728641856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jul. 13, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ACADIA PHARMACEUTICALS INC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001070494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul. 13,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-50768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">06-1376651<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">12830 El Camino Real<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">558-2871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ACAD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>d533087d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="acad-20230713.xsd" xlink:type="simple"/>
    <context id="duration_2023-07-13_to_2023-07-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070494</identifier>
        </entity>
        <period>
            <startDate>2023-07-13</startDate>
            <endDate>2023-07-13</endDate>
        </period>
    </context>
    <dei:EntityRegistrantName
      contextRef="duration_2023-07-13_to_2023-07-13"
      id="Hidden_dei_EntityRegistrantName">ACADIA PHARMACEUTICALS INC</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="duration_2023-07-13_to_2023-07-13">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2023-07-13_to_2023-07-13"
      id="Hidden_dei_EntityCentralIndexKey">0001070494</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2023-07-13_to_2023-07-13">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2023-07-13_to_2023-07-13">2023-07-13</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2023-07-13_to_2023-07-13">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2023-07-13_to_2023-07-13">000-50768</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2023-07-13_to_2023-07-13">06-1376651</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2023-07-13_to_2023-07-13">12830 El Camino Real</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2023-07-13_to_2023-07-13">Suite 400</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2023-07-13_to_2023-07-13">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2023-07-13_to_2023-07-13">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2023-07-13_to_2023-07-13">92130</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2023-07-13_to_2023-07-13">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2023-07-13_to_2023-07-13">558-2871</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2023-07-13_to_2023-07-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2023-07-13_to_2023-07-13">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2023-07-13_to_2023-07-13">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2023-07-13_to_2023-07-13">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2023-07-13_to_2023-07-13">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2023-07-13_to_2023-07-13">ACAD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2023-07-13_to_2023-07-13">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2023-07-13_to_2023-07-13">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MB_W8<JWW&T]\N]/FACT9973+EDQ_S1826G:E$O&$I8J+E$BV&5N^>W/K]4Q
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M/UY_ 5!+ 0(4 Q0    ( "^ \E8'04UB@0   +$    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ +X#R5CI$Z9ON
M*P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ +X#R5IE<G",0!@  G"<  !,              ( !S $  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    "  O@/)6M:6S[&L$   Y$0  &
M            @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ +X#R5I^@&_"Q @  X@P   T              ( !K@P  'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    "  O@/)6EXJ[',     3 @  "P
M    @ &*#P  7W)E;',O+G)E;'-02P$"% ,4    "  O@/)6'#AEZC\!   \
M @  #P              @ %S$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%
M  @ +X#R5B0>FZ*M    ^ $  !H              ( !WQ$  'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ +X#R5F60>9(9 0  SP,
M !,              ( !Q!(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
/  D "0 ^ @  #A0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d533087d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acadia-pharm.com//20230713/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName -  d533087d8k.htm 7</Log>
  </Logs>
  <InputFiles>
    <File doctype="8-K" original="d533087d8k.htm">d533087d8k.htm</File>
    <File>acad-20230713.xsd</File>
    <File>acad-20230713_lab.xml</File>
    <File>acad-20230713_pre.xml</File>
    <File>d533087dex991.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d533087d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 23
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d533087d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "acad-20230713_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "acad-20230713_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "acad-20230713.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "acad",
   "nsuri": "http://www.acadia-pharm.com/20230713",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d533087d8k.htm",
      "contextRef": "duration_2023-07-13_to_2023-07-13",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.acadia-pharm.com//20230713/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d533087d8k.htm",
      "contextRef": "duration_2023-07-13_to_2023-07-13",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acadia-pharm.com//20230713/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acadia-pharm.com//20230713/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acadia-pharm.com//20230713/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acadia-pharm.com//20230713/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acadia-pharm.com//20230713/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acadia-pharm.com//20230713/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acadia-pharm.com//20230713/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acadia-pharm.com//20230713/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acadia-pharm.com//20230713/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acadia-pharm.com//20230713/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acadia-pharm.com//20230713/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acadia-pharm.com//20230713/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acadia-pharm.com//20230713/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acadia-pharm.com//20230713/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acadia-pharm.com//20230713/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acadia-pharm.com//20230713/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acadia-pharm.com//20230713/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acadia-pharm.com//20230713/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acadia-pharm.com//20230713/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acadia-pharm.com//20230713/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acadia-pharm.com//20230713/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acadia-pharm.com//20230713/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acadia-pharm.com//20230713/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001193125-23-188839-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-23-188839-xbrl.zip
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MZW'-;5NT=I3)ZBPW-]V9KZ_JG>-^_@%02P,$%     @ +X#R5K#TYI"!!@
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M9 L7E/DLH'X$MT7++^&2!7TXC2+XK-.DZE,2<4_"?JX:4?;?6/\UT]W#BQ\
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MF+8]^UFF#14?9BH"Y@OO 8=%VW;)'#H!,[?035Z7#2*>GVF_$QP^.9S02/[
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M\;A>&*#ODJR+/ /\LE+?VE3)@('2 JHCF%@#!*&)1//-Y0CX)UF!RFE-B$M
M%OH:UWUF(7Z#9;TF/<T1"^Q$=>CA&9X(PP#(#"JTKPOG?"HP[-Z] ORT#,JT
MO"AHQ_0S(H"$_D! KP#F5)$=!#62L@%Y!TYKN:K-$0SJ  <@ 2#:CYJK L)8
MCT1*(=^I[BK7$X@\Q(.ZTM"GW(X0%H&YF'Z(<KP/'0'!L?[9#*2 45620YCZ
MT!Q<\NYPXZ%]=%*L$8=6R G@X(*"R8A'/+;44IUHWUBR,$GD2 _":#[D&%X
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M8 '%LO7UHI3S2M^SIW '(E;GXG]02P,$%     @ +X#R5DR[/G9I'0  0)(
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MDAAC;F%;<]ON1E9"@1P EM!L+'A2<6@R;(>P+T$0-HTGNXI@>9]=I/!BS3+
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M<XU-,J)L+)$CC+D.']TT9;Q_<(U3&7EI^<X>^,J^,<F$!@8'-L8H4A1EH*+
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MHQ'LY%-MDKQVT%I&;R]0 _(4\LD+)MPO4MY3@>D"CL%P(@,>J ^);7GI0*K
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MH-X'+>K-1K6YW:J_$,7)Y$YRFY&?VUL[^-SY"A<_7IX<[_\?4$L! A0#%
M  @ +X#R5L3BP\$_ P  60L  !$              ( !     &%C860M,C R
M,S W,3,N>'-D4$L! A0#%     @ +X#R5K#TYI"!!@  ND8  !4
M     ( !;@,  &%C860M,C R,S W,3-?;&%B+GAM;%!+ 0(4 Q0    ( "^
M\E85=Y;[R@0  $@L   5              "  2(*  !A8V%D+3(P,C,P-S$S
M7W!R92YX;6Q02P$"% ,4    "  O@/)6LV:1?V09  #2FP  #@
M    @ $?#P  9#4S,S X-V0X:RYH=&U02P$"% ,4    "  O@/)63+L^=FD=
M  ! D@  $0              @ &O*   9#4S,S X-V1E>#DY,2YH=&U02P4&
2      4 !0!  0  1T8

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
